BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12596958)

  • 21. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
    Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concordance of HPV, conventional smear, colposcopy, and conization results in cervical dysplasia.
    Aydogan Kirmizi D; Baser E; Demir Caltekin M; Onat T; Sahin S; Yalvac ES
    Diagn Cytopathol; 2021 Jan; 49(1):132-139. PubMed ID: 33118711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
    Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
    Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia.
    Monsonego J; Pintos J; Semaille C; Beumont M; Dachez R; Zerat L; Bianchi A; Franco E
    Int J Gynecol Cancer; 2006; 16(2):591-8. PubMed ID: 16681731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.
    Katki HA; Gage JC; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Managing atypical squamous cells of undetermined significance in Papanicolaou smears.
    Morin C; Bairati I; Bouchard C; Fortier M; Roy M; Moore L; Meisels A
    J Reprod Med; 2001 Sep; 46(9):799-805. PubMed ID: 11584480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of the reliability of repeat cervical smears and colposcopy in patients with abnormal cervical cytology.
    Mayeaux EJ; Harper MB; Abreo F; Pope JB; Phillips GS
    J Fam Pract; 1995 Jan; 40(1):57-62. PubMed ID: 7807039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months.
    Bulk S; Bulkmans NW; Berkhof J; Rozendaal L; Boeke AJ; Verheijen RH; Snijders PJ; Meijer CJ
    Int J Cancer; 2007 Jul; 121(2):361-7. PubMed ID: 17354241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
    Bokan T; Ivanus U; Jerman T; Takac I; Arko D
    Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of cervical intraepithelial neoplasia in women with atypical squamous or glandular cells of undetermined significance cytology: a prospective study.
    Wensveen C; Kagie M; Veldhuizen R; De Groot C; Denny L; Zwinderman K; Trimbos B
    Acta Obstet Gynecol Scand; 2003 Sep; 82(9):883-9. PubMed ID: 12911453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.
    Wentzensen N; Schwartz L; Zuna RE; Smith K; Mathews C; Gold MA; Allen RA; Zhang R; Dunn ST; Walker JL; Schiffman M
    Clin Cancer Res; 2012 Aug; 18(15):4154-62. PubMed ID: 22675168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.
    Salmerón J; Lazcano-Ponce E; Lorincz A; Hernández M; Hernández P; Leyva A; Uribe M; Manzanares H; Antunez A; Carmona E; Ronnett BM; Sherman ME; Bishai D; Ferris D; Flores Y; Yunes E; Shah KV
    Cancer Causes Control; 2003 Aug; 14(6):505-12. PubMed ID: 12948281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
    Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL) and histology.
    Rossetti D; Gerli S; Saab JC; Di Renzo GC
    J Med Liban; 2000; 48(3):127-30. PubMed ID: 11268564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study.
    Tidy JA; Lyon R; Ellis K; Macdonald M; Palmer JE
    BJOG; 2020 Sep; 127(10):1260-1267. PubMed ID: 32279427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human papillomavirus testing as triage for atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions: sensitivity, specificity, and cost-effectiveness.
    Kaufman RH; Adam E; Icenogle J; Reeves WC
    Am J Obstet Gynecol; 1997 Oct; 177(4):930-6. PubMed ID: 9369847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening.
    Coste J; Cochand-Priollet B; de Cremoux P; Le Galès C; Cartier I; Molinié V; Labbé S; Vacher-Lavenu MC; Vielh P;
    BMJ; 2003 Apr; 326(7392):733. PubMed ID: 12676841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.
    Schiffman M; Herrero R; Hildesheim A; Sherman ME; Bratti M; Wacholder S; Alfaro M; Hutchinson M; Morales J; Greenberg MD; Lorincz AT
    JAMA; 2000 Jan; 283(1):87-93. PubMed ID: 10632285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.